Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
21,532 results
  • Everolimus: Longer-term CERTITUDE. [Editorial]
    Liver Transpl 2019Mousa OY, Keaveny AP
  • The approval in 2013 by the Federal Drug Administration of everolimus [EVR] for use in liver transplant [LT] recipients was the l arrival of a "new kid on the block" in immunosuppression [IS] therapy. While sirolimus, another mammalian target of rapamycin [mTOR] inhibitor had been used off-label for many years prior to the approval of EVR, the latter's shorter terminal half-life and quicker time …
  • Temsirolimus Metabolic Pathways Revisited. [Journal Article]
    Xenobiotica 2019; :1-30Shokati T, Hartmann M, … Christians U
  • 1. Temsirolimus, a derivative of sirolimus, exhibits potent antitumor properties. It was the goal of this study to identify yet unknown temsirolimus metabolites generated after incubation with human liver microsomes. Previously, 23-hydroxy-, 24-hydroxy, 12-hydroxy, hydroxy-piperidine and 27-O-desmethyl temsirolimus had been described. 2. Metabolite strutures were identified using high-resolution …
New Search Next